Search

Your search keyword '"Barrientos, J"' showing total 444 results

Search Constraints

Start Over You searched for: Author "Barrientos, J" Remove constraint Author: "Barrientos, J"
444 results on '"Barrientos, J"'

Search Results

1. Efficiency calibration of the BRIKEN detector: the world largest counter for beta-delayed neutrons

5. Narnaviruses: novel players in fungal–bacterial symbioses

8. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia

11. Study of decay properties of Ba to Nd nuclei (A~160) relevant to the formation of the r-process rare-earth peak

12. Study of decay properties for Ba to Nd nuclei relevant for the formation of the r-process rare-earth peak (A∼160)

14. Formation of Common Investment Networks by Project Establishment between Agents

15. Risk-Seeking versus Risk-Avoiding Investments in Noisy Periodic Environments

21. Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study

31. Half-life Measurement Using Implant-\((\beta -\gamma )\) Time Correlations in the Region of Neutron-rich Lanthanides

32. A Dynamical Systems Model for Understanding Behavioral Interventions for Weight Loss

35. A Kohonen Network for Modeling Students’ Learning Styles in Web 2.0 Collaborative Learning Systems

37. Effect of feeding type and artisanal process in microstructural and physicochemical parameters of fresh and ripened goat cheese

38. Measuring the β-decay Properties of Neutron-rich Exotic Pm, Sm, Eu, and Gd Isotopes to Constrain the Nucleosynthesis Yields in the Rare-earth Region

40. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

43. PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

44. P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE

48. Updated efficacy including subgroup analyses and safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukaemia/small lymphocytic lymphoma: 35

49. Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors: 34

Catalog

Books, media, physical & digital resources